Approval · Notice of Compliance 15116 · 2013
ABREVA: Notice of Compliance 15116
Issued December 6, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15116
- Date
- December 6, 2013
- Company
- Glaxosmithkline Consumer Healthcare UlcMississauga, Ontario, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Add clarity to the pm, update safety statements, include claims that are within the current indication, adding 4 references to support new proposed statements in pm
- Therapeutic class
- Virtal entry blockin agent. cold sore / fever blister treatment
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABREVA | Not yet assigned | — |
Medicinal ingredients
- DOCOSANOL 10 PER